Lanxess - Estimates
KPI (in Euro m)Q2 2021FY 2021Q2 2022 EFY 2022 E
SalesNumber of Estimates913
EBITDA pre exceptionalsNumber of Estimates913
EBITDA pre exceptionalsHighest325.01,228.0
EBITDA pre exceptionalsConsensus277.01,010.0312.21,165.7
EBITDA pre exceptionalsMedian315.01,179.0
EBITDA pre exceptionalsLowest286.01,075.8
Net income after minorities pre exceptionalsNumber of Estimates39
Net income after minorities pre exceptionalsHighest132.1490.4
Net income after minorities pre exceptionalsConsensus119.0417.0124.3430.9
Net income after minorities pre exceptionalsMedian131.9442.1
Net income after minorities pre exceptionalsLowest108.8330.5
EPS pre exceptionals (in Euro)Number of Estimates49
EPS pre exceptionals (in Euro)Highest1.535.68
EPS pre exceptionals (in Euro)Consensus1.384.831.395.00
EPS pre exceptionals (in Euro)Median1.395.12
EPS pre exceptionals (in Euro)Lowest1.243.87
Capex (excl. acquisitions)Number of Estimates311
Capex (excl. acquisitions)Highest136.0525.0
Capex (excl. acquisitions)Consensus92.0479.0126.5502.2
Capex (excl. acquisitions)Median127.0500.0
Capex (excl. acquisitions)Lowest116.4477.0

Consensus includes market expectations regarding the contribution from IFF Microbial Control. The company expects closing of the IFF MC deal in the third quarter of 2022.

Last Update: May 13, 2022. Provided by

Vara Research


This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.